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Abstract
Epstein-Barr virus (EBV) causes nasopharyngeal carcinoma (NPC) in endemic regions,
where almost every tumor is EBV-positive. In Western populations, NPC is rare, and
human papillomavirus infection (HPV) has been suggested as another viral cause. We
validated multiplex serology with molecular tumor markers, to define EBV-positive,
HPV-positive and EBV-/HPV-negative NPCs in the United Kingdom, and analyzed
survival differences between those groups. Sera from NPC cases (n = 98) and age-
and sex-matched controls (n = 142) from the Head and Neck 5000 clinical cohort
study were analyzed. IgA and IgG serum antibodies against 13 EBV antigens were
measured and compared with EBER in situ hybridization (EBER-ISH) data of 41 NPC
tumors (29 EBER-ISH positive, 12 negative). IgG antibodies to EBV LF2 correctly
diagnosed EBV-positive NPCs in 28 of 29 cases, while all EBER-ISH negative NPCs
were seronegative to LF2 IgG (specificity = 100%, sensitivity = 97%). HPV early anti-
gen serology was compared to HPV molecular markers (p16 expression, HPV DNA
and RNA) available for 41 NPCs (13 positive, 28 negative). Serology matched molecu-
lar HPV markers in all but one case (specificity = 100%, sensitivity = 92%). EBV and
HPV infections were mutually exclusive. Overall, 67% of the analyzed NPCs were
defined as EBV-positive, 18% as HPV-positive and 14% as EBV/HPV-negative. There
was no statistical evidence of a difference in survival between the three groups.
These data provide evidence that both, EBV-positive and HPV-positive NPCs are
present in a low incidence country, and that EBV and HPV serum antibodies correlate
with the viral status of the tumor.
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1 | INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a squamous cell cancer arising
from the lining of the nasopharynx. The incidence of nasopharyngeal
cancer varies widely across the world. Globally, the incidence rate is
below one per 100 000 person-years.1 However, incidence rates in
NPC endemic regions, including Southeast Asia, North Africa, China
and the Arctic, are up to 30 times higher.2
In high-incidence or endemic regions, Epstein-Barr-virus (EBV) is
uniformly associated with NPC development.3 Elevated antibody
levels to EBV proteins in NPC patients have been described since
19663 in many case-control4-6 and prospective studies7,8 and are a
useful tool for diagnosis and disease prediction in endemic
populations. Until recently, these serological analyses were limited to
IgA antibody levels against the viral capsid antigen (VCA), EBV nuclear
antigen 1 (EBNA1) and early antigen diffuse (EA-D). In 2018, Coghill
et al described a novel EBV antibody risk stratification signature, con-
sisting of 14 IgA and IgG antibodies against diverse EBV proteins for
the prediction of NPC development in Taiwan, a high-incidence
region.9 This model for NPC prediction showed an accuracy of 93%
for detecting NPCs, compared with an accuracy of 82% for VCAp18/
EBNA1 IgA biomarkers alone (P < .01).
In low-incidence regions, other risk factors besides EBV infection
have been described to be associated with NPC development.10 The
role of smoking as a risk factor has been examined in several studies
in both, low incidence and endemic regions, and the risk associated
with smoking has been shown to be higher in low incidence coun-
tries.11 More recently, several studies also described human papillo-
mavirus (HPV) as a risk factor for NPCs in low incidence regions,
although the causal link remains under debate.12-15
HPV, especially type 16, is established as a causal agent for the
development of oropharyngeal carcinoma (OPC),16,17 while the preva-
lence of HPV-driven head and neck tumors outside the oropharynx is
low.18 However, NPCs and OPCs share properties that distinguish
them from other head and neck cancers, like their predominantly viral
etiology, early age at disease onset, and similar clinical characteristics,
especially early lymph node involvement.19 In OPCs, early antigen
HPV serology (especially antibodies against the HPV16 oncoprotein
E6) has been shown to be very strongly associated with molecularly
defined HPV-positive OPCs, both at diagnosis and prospec-
tively.17,20,21 HPV detection in NPCs has been limited to p16 immu-
nohistochemistry (IHC) and HPV DNA detection by PCR or in situ
hybridization (ISH).12-15 Currently, no serological assay has been vali-
dated for detecting HPV-positive NPCs.
The aim of our study was thus to examine whether EBV and HPV
serum antibodies or antibody pattern can differentiate NPCs associ-
ated with EBV, with HPV, and those not associated with either virus,
and to describe the roles of EBV and HPV infection in the develop-
ment of NPCs in a low incidence region. These data have the potential
to make important contributions to the clinical management of NPCs.
While screening approaches are not reasonable in the United King-
dom, due to low NPC incidence, the viral status of the tumor could
reveal potential survival differences and underline the need for
specific treatment regimens. HPV-driven OPCs have been shown to
have a much better survival than HPV-negative OPCs, and can be
identified by HPV16-specific antibodies.22 Existing analyses of sur-
vival of EBV-positive, HPV-positive and EBV/HPV-negative NPCs are
sparse and contradictory13,23 and need to be further investigated.
To this end, we examined the molecular and serological EBV and
HPV status of NPC cases from the United Kingdom, a country with
low NPC incidence (0.27 per 100 00024). The analysis was based on
the Head and Neck 5000 clinical cohort study,25 and included 98 inci-
dent NPC cases and 142 age- and sex-matched laryngeal squamous
cell carcinoma cases (LSCCs) as controls. We used molecular analyses
to validate serology for both, EBV and HPV, and calculated sensitivi-
ties and specificities for NPC diagnosis. Moreover, we defined three
groups, NPCs associated with either EBV infection or HPV infection,
and EBV/HPV-negative NPCs, and compared risk factors, histological
subtypes and survival.
2 | MATERIALS AND METHODS
2.1 | Study population
The Head and Neck 5000 clinical cohort study has been described in
detail elsewhere.25,26 Briefly, 5511 individuals with newly diagnosed
head and neck cancer were recruited in 76 centers across the United
Kingdom between 2011 and 2014.
The current analysis included 98 incident nasopharyngeal carci-
noma cases (ICD-O-3 C11) and as controls 142 age- and sex-matched
laryngeal squamous cell carcinomas (LSCC; ICD-O-3 C32) for which no
EBV-positive cases27 and <5% HPV-positive cases18 are expected
(Table 1). Extended pathology reports were requested and available for
76 NPC cases. We cross-checked information captured in histopathol-
ogy reports against clinical data, and anatomical site misclassification
was ruled out, to the best of our knowledge, for 87% (66 of 76) of these
NPC cases. Routine clinical measures, including EBER-ISH and p16,
were extracted from the histopathological reports.
What's new?
While Epstein-Barr virus (EBV) causes almost all nasopharyn-
geal carcinoma (NPC) in endemic regions, human papilloma-
virus (HPV) may also cause NPCs in low-incidence, Western
populations. Here, the authors used molecular tumor
markers to validate EBV and HPV multiplex serology to
define the viral status of NPCs in the United Kingdom. IgG
antibodies to the EBV antigen LF2 and HPV early antigen
serology were highly specific and sensitive to identify EBV-
and HPV-positive NPCs, respectively. The results show that
both EBV-positive and HPV-positive NPCs are present in a
low-incidence country, and that EBV and HPV serum anti-
bodies correlate with the viral status of the tumor.
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2.2 | Molecular analysis of tumor tissue
2.2.1 | EBER-ISH and p16 IHC
Epstein-Barr virus small RNA 1 (EBER-1) in situ hybridization (EBER-
ISH) is the gold standard for detecting the EBV genome in tumor tis-
sue.28 EBER-ISH status was available for a total of 41 NPCs. For
34 NPC cases, it was obtained from pathology reports of the clinical
centers; for nine NPCs (including two of the above group), formalin-
fixed paraffin-embedded (FFPE) tumor tissue was sectioned according
to standard protocols29 and sent for EBER-ISH staining and reading
(Leica ISH EBER probe, automated BOND system) to Severn Pathol-
ogy, an ISO-accredited medical laboratory (Bristol, United Kingdom).
p16 immunohistochemistry (IHC) is the clinical gold-standard for
assessing HPV status of OPCs. p16 status was available for a total of
41 NPCs, for 20 it was provided by clinical centers and for 22 deter-
mined by staining FFPE tissue sections for p16 at the National Center
for Tumor Diseases (NCT) tissue bank (Heidelberg, Germany).
2.2.2 | HPV DNA and RNA analysis
HPV molecular analysis included isolation of HPV DNA and RNA
according to standard protocols with utmost care to avoid sample
cross-contamination.29
After DNA and RNA extraction, Multiplex Papillomavirus
Genotyping30,31 (MPG) was used to analyze DNA for the presence of
51 HPV types including all known high-risk HPV types. RT-PCR and
hybridization was used to detect HPV type-specific E6*I RNA for the
HPV type(s) detected in the MPG assay.29 Combined HPV DNA and
RNA detection is considered the laboratory gold-standard for
assessing HPV status of OPCs.21
2.2.3 | Histology
Histology data were obtained for 60 NPC cases, either by extracting
data from pathology reports (for 37 cases), or by reviewing and classi-
fying the tumor tissue (for 23 cases) by a pathologist.
Cases were categorized into keratinizing NPC (WHO type I),
nonkeratinizing differentiated NPC (WHO type II), nonkeratinizing
undifferentiated NPC (WHO type III), nonkeratinizing NPC not other-
wise specified (WHO type II or III), and basaloid squamous NPC. A
total number of 50 cases had an explicit WHO classification of type I,
II or III.
2.2.4 | EBV serology
Serological testing of blood taken at diagnosis was performed with
multiplex serology, a high-throughput assay for simultaneous detec-
tion of serum antibodies against a large number of antigens.32 Testing
for EBV antibodies included separate IgA and IgG detection, as indi-
cated by a recently published NPC risk stratification signature.9 Sera
were preincubated at 1:50 dilution for IgA testing (final dilution
1:100) and at 1:5000 dilution for IgG testing (final dilution 1:10 000)
in a serum preincubation buffer based on PBS with 2 mg/mL casein
and additionally containing 2 g/L of lysate proteins of Escherichia coli
overexpressing glutathione-S-transferase (GST)-tag, 5 g/L polyvinyl
alcohol and 8 g/L polyvinyl-pyrrolidone.33
EBV serology was based on 13 antigens. VCAp18, EBNA1 peptide
(pep), EBNA1 truncated (trunc), ZEBRA and EA-D were previously vali-
dated for multiplex serology.34 The remaining eight antigens (BXLF1,
LF2, BZLF1, BORF1, BFRF1, BGLF2, BRLF1, BPLF1) derived from an
NPC-specific risk stratification signature9 and were adapted for multi-
plex serology by recombinant expression as GST-tagged fusion proteins
in E. coli. The antigens ZEBRA (245 amino acids) and BZLF1 (43 amino
acids) display antigenic domains from the same protein, and show an
identity of 98% in their 43 overlapping amino acids. For consistency,
both, the previously validated ZEBRA and the BZLF1 as part of the
NPC-specific risk stratification signature, were included in our assay.
Three antigens representing the major capsid protein VP1 of the three
human polyomaviruses (HPyV) JC, BK and HPyV6 were included as
specificity controls (no association with NPC was expected).
Bound serum antibodies were detected with goat anti-Human
IgG-Biotin (1:1000, #109-065-098, Jackson ImmunoResearch, West
Grove, Pennsylvania) and goat anti-Human IgA-Biotin (1:1000,
#109-065-011, Jackson ImmunoResearch), respectively, and
TABLE 1 NPC case and LSCC control group characteristics
NPC cases
(n = 98)
LSCC controls
(n = 142) P-value
Mean age (SD) 53 (13) 55 (11) .42
Sex .97
Male 75 (77%) 109 (77%)
Female 23 (23%) 33 (23)%
Smokinga <.01
Never 21 (33%) 5 (5%)
Former 30 (47%) 61 (65%)
Current 13 (20%) 28 (30%)
Alcohol consumptiona .01
Nondrinker 28 (41%) 29 (30%)
Moderate 18 (26%) 20 (21%)
Hazardous 21 (31%) 32 (33%)
Harmful 1 (1%) 16 (16%)
Socioeconomic statusa .59
1—least deprived 23 (25%) 33 (26%)
2 19 (21%) 26 (21%)
3 19 (21%) 32 (25%)
4 13 (14%) 21 (17%)
5—most deprived 17 (19%) 14 (11%)
Abbreviations: LSCC, laryngeal squamous cell carcinoma; NPC, nasopha-
ryngeal carcinoma.
aNumbers may not add up to 100% due to missing data.
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subsequently stained with streptavidin-R-phycoerythrin (1:750,
MOSS Inc., Elk Grove Village, Illinois).
2.2.5 | HPV serology
HPV serology was performed at a final serum dilution of 1:100 with a
triple isotype-specific (IgG/IgM/IgA) goat anti-Human antibody as
described previously.32 Analysis included serum antibodies against
early (E6 and E7) and late (L1) proteins of high-risk HPV types 16, 18,
31, 33, 35, 45, 52 and 58, and additionally antibodies against early
proteins E1, E2 and E4 of HPV16 and HPV18. We defined seroposi-
tivity based on the standard definition (HPV16 E6 antibodies >1000
MFI [median fluorescence intensity]) which has been validated for
HPV-driven OPCs.21 In addition, we applied an extended approach
previously shown for neck squamous cell carcinoma from unknown
primary that includes the standard definition but alternatively allows
positivity to three out of four early antigens (E1, E2, E6, E7) for
HPV16 and HPV18, or positivity to two early antigens (E6 and E7) for
HPV 31, 33, 35, 45, 52 and 58. A serum sample was considered HPV
seropositive if either the standard or the extended definition was met.
Overall, 12 HPV16-positive cases were defined with the standard def-
inition, and five cases were defined as HPV18-positive using the
extended definition.
2.3 | Statistics
Statistical tests for categorical analyses included chi-square test, and
Fisher's exact test for small (n < 6) cell counts. t-Test was used to com-
pare the mean age of the case and control groups. Differences in MFI
values of cases and controls were calculated by Mann-Whitney test.
Smoking was categorized as never, former or current, and alcohol
consumption was analyzed in the categories nondrinker, moderate,
hazardous or harmful. Detailed information on smoking and alcohol
history was obtained at baseline via a self-reported questionnaire as
described before.35 Since there was only one harmful drinker among
the NPC cases, the “harmful” and “hazardous” categories were com-
bined in subsequent analyses (Table 1).
Socioeconomic status was categorized in five categories from
“1—least deprived” to “5—most deprived” based on the English Index
of Multiple Deprivation (IMD) 2010 quintiles using participants' home
postcode.36 This area-based index of deprivation is derived from mea-
sures of income, education, crime and barriers to housing.
We used receiver operating characteristic (ROC) analysis of
41 cases with EBER-ISH status to define antigen-specific cut-offs for
the EBV antigens based on ≥90% specificity. Resulting cut-off values
are listed in Table S1. The technical minimum cut-off above assay
background is 30 MFI for IgA at 1:100 dilution and IgG at 1:10 000
dilution, and 50 MFI for the triple isotype-specific (IgG/IgM/IgA) anti-
body at 1:100 dilution.
Odds ratios for the association of EBV antibodies with NPC were
calculated using unconditional logistic regression with 95% confidence
intervals (CI) adjusted for age, sex, smoking and alcohol consumption.
All NPC cases and controls were included in regression models, and
EBV antigens were treated as binary variables, based on the cut-offs
described above.
Final EBV status of NPCs was determined if available by
(a) EBER-ISH status from FFPE, (b) EBER-ISH data from diagnostic
pathology reports, or in the absence of EBER-ISH data, (c) EBV serol-
ogy. Final HPV status was determined if available by (a) p16 status
from FFPE, (b) clinical p16 data, (c) positivity to both HPV DNA and
RNA, or in the absence of HPV molecular data, (d) seropositivity as
described above.
Overall survival of EBV-positive, HPV-positive and EBV/HPV-
negative NPCs, as well as the overall survival stratified by WHO
type I, II and II, was plotted in a Kaplan-Meier graph. Cox proportional
regression models adjusted for age and sex were used to estimate
hazard ratios.
All statistical analyses were performed using GraphPad Prism 8.0
(GraphPad Software, Inc., La Jolla, California), Stata 15.0 (StataCorp.,
College Station, Texas) or SAS enterprise guide 7.1 (SAS Institute,
Cary, North Carolina). A P-value of .05 was considered as statistically
significant.
3 | RESULTS
3.1 | Participant characteristics
The nasopharyngeal carcinoma cases (n = 98) and the laryngeal squa-
mous cell carcinoma cases used as a control group (n = 142) did not
differ in mean age, sex and socioeconomic status (Table 1). However,
the proportion of never smokers and nondrinkers was significantly
higher in NPC cases than among LSCCs (33% vs 5%, P < .01, and 41%
vs 30%, P = .01, respectively).
3.2 | EBV serology validation
All case and control sera were tested for the presence of 26 EBV anti-
body markers, including IgA and IgG antibodies for 13 antigens. IgA
antibody responses to all 13 antigens and IgG antibody responses to
all antigens except one (VCAp18) were significantly higher among
cases than controls (Figure S1). No significant differences between
cases and controls were seen in both IgG and IgA antibody responses
to all three human polyomaviruses, with the exception of low-level
IgA responses to BK virus (median MFI among controls 306 MFI,
median MFI among cases 149 MFI, P < .01, compared to 300 and
345 MFI among cases and controls for IgG respectively, P = .52). Odds
ratios adjusted for age, sex, alcohol and smoking showed strong asso-
ciations of EBV antibody responses with NPC (Table S2). A higher risk
of NPC was observed for all anti-EBV antibodies except for VCAp18
IgG, with odds ratios ranging from 2.7 (95% CI 1.4-5.0) for VCAp18
IgA to 80.5 (95% CI 25.0-258.8) for LF2 IgG and 132.3 (95% CI
17.1-∞) for BGLF2 IgA (Figure 1 and Table S2).
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EBV tumor status based on EBER-ISH analysis was available for
41 NPC cases (29 positive, 12 negative). To investigate whether EBV
tumor status was reflected by serological markers, IgA and IgG anti-
bodies against 13 EBV proteins were compared to EBER-ISH tumor
status for validation. Antigen-specific cut-offs were defined using
ROC analysis with EBER-ISH status as gold-standard, and a minimum
specificity of 90%. The resulting sensitivities for the 26 combinations
of 13 antigens and both IgA and IgG antibodies ranged from 7% for
VCAp18 IgG to 97% for BGLF2 IgG and LF2 IgG (Table S1). Compar-
ing IgA and IgG antibody responses, a higher sensitivity of IgG anti-
bodies was observed for 9 out of 13 antigens, whereas IgA antibodies
were more sensitive for four antigens; the latter was particularly evi-
dent for VCAp18 (66% for IgA, 7% for IgG).
Examining individual antibody performances, LF2 IgG antibodies
were able to differentiate EBV-positive NPCs from EBV-negative
NPCs with 97% sensitivity and 100% specificity (Figure 2). The sole
EBER-ISH positive NPC case that was not identified by LF2 IgG
was seronegative for 21 antibody markers and only seropositive to
BGLF2 IgA and IgG, EBNA1trunc and EBNA1pep IgG and VCAp18
IgA. Seroprevalence of LF2 IgG in control LSCCs was only 3%
(Figure 2). The second and third best-performing antibodies were
BGLF2 IgG with a sensitivity of 97% at 92% specificity, and BXLF1
F IGURE 1 Odds ratios (OR) and 95% confidence intervals
(CI) adjusted for age, gender, smoking and alcohol consumption for
the association of EBV IgA and IgG antibodies with NPC
F IGURE 2 Median fluorescence intensities (MFI) for antibody
responses against LF2 IgG, stratified by EBER-ISH status for 98 NPC
cases (n = 29 positive, n = 12 negative, n = 57 missing) and control
laryngeal squamous cell cancer (LSCC; n = 142). The dotted line
indicates the seropositivity cut-off (30 MFI) based on receiver
operator characteristic (ROC) analysis of NPC cases with available
EBER-ISH data
F IGURE 3 Heatmap showing EBV and HPV serostatus as well as
molecular markers (EBER-ISH and HPV DNA, HPV RNA and p16 IHC)
of all 98 NPC cases. Positivity is shown in green, negativity in red, and
black indicates nonavailable data. EBV serology is defined as
seropositivity to LF2 IgG antibodies. HPV serology is defined as either
HPV16 E6 > 1000 MFI, or positivity to three out of four early
antigens of HPV16 or of HPV18, or positivity to two type-concordant
early antigens (E6 and E7) of HPV 31, 33, 35, 45, 52 or 58
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IgG (93% and 92%, respectively). However, 10% and 17% of the
control LSCCs were seropositive for BGLF2 and BXLF1 IgG,
respectively.
BGLF2 IgA antibodies showed the strongest association with
NPC among all cases (Table S2), based on high specificity (only 1% of
control LSCCs were seropositive) but with low sensitivity (only 47%
of NPC cases were seropositive; Table S2). Even when restricting the
analysis to EBER-ISH-positive cases, the sensitivity of BGLF2 IgA anti-
bodies was much lower (76%) than for BGLF2 IgG and LF2 IgG
(both 97%).
Combining several biomarkers did not improve classification of
EBV-positive NPCs compared to single markers in this dataset. The
combination of the two best stand-alone markers (positivity for at
least one of the two), LF2 IgG and BGLF2 IgG, yielded a slightly higher
TABLE 2 Characteristics of EBV-positive, HPV-positive and EBV/HPV-negative NPC cases
EBV-positive (n = 66) HPV-positive (n = 18) EBV/HPV-negative (n = 14) P-value
Mean age (SD) 52 (14) 53 (12) 59 (9) .19
Sex .38
Male 49 (74%) 16 (89%) 10 (71%)
Female 17 (26%) 2 (11%) 4 (29%)
Stagea .50
I 5 (8%) 0 (0%) 2 (14%)
II 15 (23%) 4 (22%) 5 (36%)
III 24 (37%) 8 (44%) 2 (14%)
IV 21 (32%) 6 (33%) 5 (36%)
Treatment .38
Surgery only 1 (2%) 0 (0%) 2 (14%)
Chemoradiotherapy only 51 (77%) 15 (83%) 9 (64%)
Radiotherapy only 8 (12%) 3 (17%) 2 (14%)
Surgery and chemo/radio 3 (5%) 0 (0%) 0 (0%)
Chemotherapy only 1 (2%) 0 (0%) 0 (0%)
No treatment 2 (3%) 0 (0%) 1 (7%)
Smokinga .39
Never 14 (33%) 2 (20%) 5 (45%)
Former 19 (44%) 5 (50%) 6 (55%)
Current 10 (23%) 3 (30%) 0 (0%)
Oral sex partnersa .24
1 to 2 10 (50%) 4 (50%) 1 (20%)
3 to 4 4 (20%) 4 (50%) 2 (40%)
5 or more 6 (30%) 0 (0%) 2 (40%)
Alcohol consumptiona .10
Nondrinker 21 (48%) 1 (8%) 6 (50%)
Moderate 12 (27%) 4 (33%) 2 (17%)
Hazardous/harmful 11 (25%) 7 (58%) 4 (33%)
Ethnicity .06
White 52 (79%) 18 (100%) 13 (93%)
Non-white 14 (21%) 0 (0%) 1 (7%)
Histologya .0004
WHO type I 0 (0%) 3 (30%) 1 (25%)
WHO type II 8 (17%) 5 (50%) 3 (75%)
WHO type III 28 (61%) 2 (20%) 0 (0%)
WHO type II/III 9 (20%) 0 (0%) 0 (0%)
Basaloid squamous 1 (2%) 0 (0%) 0 (0%)
Abbreviations: EBV, Epstein-Barr virus; HPV, human papillomavirus.
aNumbers may not add up to 100% due to missing data.
466 SIMON ET AL.
sensitivity of 100% (vs 97% for the best marker LF2 IgG alone) but
also a lower specificity of 92% compared to 100% for LF2 IgG alone.
Combining LF2 IgG and BGLF2 IgG, the positivity for control LSCCs
was 12% and thus higher than for LF2 IgG (3%) or BGLF2 IgG (10%)
alone. The gain of sensitivity of the biomarker combination is thus
lower than the loss of specificity for both, EBV negative NPCs and
control LSCCs in our study.
Based on these data, IgG antibodies to LF2 were the best stand-
alone marker for EBV-positive NPCs in the United Kingdom as a non-
endemic region within the Head and Neck 5000 study. Thus, LF2 IgG
serology was used further to define EBV-positive NPCs by serology in
the subsequent analyses described below.
3.3 | HPV serology validation
All case and control sera were tested for the presence of antibodies
against high-risk HPV types. No significant differences were observed
for HPV antibody levels between cases and controls (data not shown).
HPV tumor status based on p16 IHC analysis was available for
41 NPC cases (13 positive, 28 negative). Nucleic acid analysis results
were obtained for 22 (RNA) and 20 (DNA) cases; two cases had inva-
lid DNA but valid RNA results. For all cases with DNA/RNA testing,
p16 status was available (Figure 3). All DNA and RNA results matched
p16 status, except two cases which were only HPV DNA positive but
HPV RNA and p16 negative. Given HPV DNA positivity is insufficient
to determine active viral involvement in tumor development,21 these
cases were not considered HPV-driven tumors.
To investigate whether HPV tumor status was reflected by sero-
logical markers, antibodies against early and late proteins of high-risk
HPV types 16, 18, 31, 33, 35, 45, 52 and 58 were measured and com-
pared to HPV molecular tumor status (as assessed by clinical and labo-
ratory gold-standards p16 and HPV DNA/RNA, respectively) for
validation. All p16 negative cases were HPV seronegative (28/28),
and all but one (12/13) p16 positive cases were seropositive, resulting
in 100% specificity and 92% sensitivity of HPV serology for molecu-
larly defined HPV-positive NPCs (positive for p16, or if p16 was not
available, positivity to both HPV DNA and RNA).
Overall, of the 18 HPV positive cases defined by molecular
analysis, 13 (72%) were HPV16 positive, four (22%) were HPV18
positive and one (6%) was positive for HPV39. Of the 13 HPV16
positive cases, 12 were also identified as HPV16-positive by serol-
ogy. The remaining HPV16-positive case (positive for HPV DNA,
RNA and p16) was missed by serology. All four HPV18-positive
cases based on molecular analysis were also defined as
HPV18-positive by serology. The one HPV39-positive case by HPV
DNA/RNA was likewise defined as seropositive to HPV18,
suggesting antibody cross-reactivity between these two closely
related HPV types (HPV39 was not included in the serological anal-
ysis). Altogether, serology matched molecular analysis in all except
one case (explained by cross-reactivity), and one case was missed
by serology.
3.4 | EBV-positive, HPV-positive and EBV/HPV-
negative NPCs
Overall, including molecular tumor markers and serology, 67% of the
analyzed NPCs were exclusively EBV-positive, 18% were exclusively
HPV-positive and 14% were not associated with either of these viral
infections (Figure 3).
Comparing the characteristics of EBV-positive, HPV-positive
and EBV/HPV-negative NPCs (Table 2) revealed no strong evidence
for significant differences among the three groups, despite of histol-
ogy. Participants with EBV- and HPV-positive NPCs tended to be
younger (52 and 53 years vs 59 years for EBV/HPV-negative NPCs,
P = .19). The proportion of nondrinkers was lower for HPV-positive
NPCs (8%) than for EBV-positive and EBV/HPV-negative NPCs
(48% and 50%, respectively, P = .10). There was no current smoker
in the group of EBV/HPV-negative NPCs, in contrast to 23% and
30% among EBV-positive and HPV-positive NPCs (P = .39). The his-
tological classification of EBV-positive, HPV-positive and EBV/HPV-
negative NPCs was significantly different among the three groups
(P = .0004; Figure S2). Of four WHO type I cases, three were HPV-
positive (75%), while 28 of 30 WHO type III cases were positive for
EBV (93%). Among the 46 EBV-positive NPCs, all but one case with
basaloid squamous histology were WHO type II or III cases, that is,
there was no EBV-positive WHO type I NPC. Of the 10 HPV-
positive NPC, 3 (30%) were WHO type I cases and 7 (70%) were
WHO type II or III cases. Among the four EBV/HPV-negative NPC
cases with histological data, one (25%) was classified as WHO type
I and three (75%) as WHO type II.
All 18 HPV-positive NPCs were identified among white partici-
pants, while 14 (21%) of the EBV-positive NPCs were identified
among people of color, including 1 Indian, 1 Bangladeshi, 2 Chinese
F IGURE 4 Kaplan-Meier plot of all-cause mortality stratified by
EBV- and HPV-positive and EBV/HPV-negative NPCs. Survival is not
significantly different (P = .61) between EBV-positive (Reference),
HPV-positive (hazard ratio [HR] 0.47, 95% confidence interval
[CI] 0.13-1.69) and EBV/HPV-negative NPCs (HR 0.91, 95% CI
0.29-2.80)
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and 3 with any other Asian background, 1 Caribbean, 2 African and
4 of any other admixture (P = .06).
3.5 | Survival analysis
There was no statistical evidence of a difference in survival between
EBV-positive, HPV-positive and EBV/HPV-negative NPCs (P = .61;
Figure 4). When compared to EBV-positive NPCs, the hazard ratios
were 0.47 (95% CI 0.13-1.69) for HPV-positive NPCs and 0.91 (95%
CI 0.29-2.80) for EBV/HPV-negative NPCs.
Comparing survival stratified by WHO histology classification,
there was no statistical evidence of a difference in survival between
WHO type I, II and III tumors (P = .51; Figure S3).
4 | DISCUSSION
Our analysis of 98 NPC cases from the United Kingdom, a low inci-
dence region, showed that 67% of all NPCs were EBV-positive, 18%
were HPV-positive and 14% were not associated with either of these
viral infections. This finding is in accordance with the existing, yet
sparse literature, showing that 60% to 76% of NPCs in low-incidence
regions are EBV-positive and 9% to 16% are HPV-positive.12-15
For the first time, we have adapted a previously developed large
EBV antigen panel for multiplex serology, and showed that IgG anti-
bodies against LF2 are sufficient to define EBV-positive NPCs. In
addition, we provided evidence that the comprehensive HPV multi-
plex serology panel, established to determine molecular HPV status in
OPCs, also reliably identifies HPV tumor status of NPCs.
Our study was based on the Head and Neck 5000 prospective
clinical cohort study, including more than 5000 participants with
head and neck cancer. Although the number of NPC cases was lim-
ited to 98 due to the low incidence of NPCs in this nonendemic
region, this likely represents one of the largest NPC case series from
a Western country. However, to validate LF2 IgG antibodies as a
reliable stand-alone biomarker and to investigate survival differences
between EBV/HPV-positive NPCs and those not associated with
either viral infection, larger and prospective studies are needed. The
inclusion of other markers for defining EBV-positive NPCs, for exam-
ple, BGLF2 IgG, has to be re-evaluated in other studies with larger
case numbers.
One limitation of our study is the use of LSCCs as a control group.
Tobacco smoking and alcohol consumption are the largest risk factors
for LSCCs, and create an imbalance between cases and controls,
which we have adjusted for in our analyses. Since we only used the
laryngeal cases to check whether antibodies distinguish between
NPCs and non-NPCs, they display a suitable control group, as LSCCs
are not known to be associated with EBV infection.27 LSCC is rarely
(<5%)18 associated with HPV infection, however, we have not calcu-
lated risk estimates for HPV serology that could have been affected
by HPV-positive LSCCs. Among people with head and neck cancer,
LSCCs are the most anatomically different and distant to NPCs, which
rules out misclassification bias. There is potential misclassification
between LSCCs and OPCs, which however does not affect our analy-
sis, as we expect both, LSCCs and OPCs, to be EBV-negative.
As a strength of our study, we requested extended histopathol-
ogy reports and cross-checked information between those against the
clinical data, to confirm tumor origin and rule out anatomical site mis-
classification as far as possible, which has been discussed as a poten-
tial explanation for HPV-positive NPCs in the past.14
The extended antigen panel we used for EBV serology is based on
a previous study that described differing IgA and IgG antibody
responses in NPC cases and controls from Taiwan, thus reflecting anti-
body pattern in a high incidence region.9 All antigens performed well in
differentiating NPC cases and controls from the United Kingdom,
where NPC incidence is low. Although a lower proportion of NPCs in
low incidence regions are associated with EBV infection, the EBV-
positive NPCs seem to be broadly serologically similar to NPCs from
high incidence regions. However, IgG antibodies to one antigen, LF2,
were sufficient to differentiate between EBV-positive and EBV-
negative NPCs in our study, rather than a panel of 14 IgA and IgG anti-
bodies.9 These findings need to be confirmed with larger case numbers.
Our cut-off values were based on relatively few cases with available
EBER-ISH data. Thus, confidence intervals are wide (LF2 IgG, sensitiv-
ity = 96.6% [95% CI 82.2-99.9], specificity = 100% [95% CI
73.5-100.0], Table S1). However, larger case numbers to further evalu-
ate the role of EBV antigens in NPCs are available in endemic countries.
The standard EBV antigens, VCAp18 and EBNA1, both needed
very high cut-off values to differentiate between EBV infected indi-
viduals and NPC cases, since they are not only markers for NPC, but
also for EBV infection, and present in almost every EBV-infected indi-
vidual. However, we used the full-length VCA-p18 as an antigen. The
most EBV-specific antigenic domain comprises the C-terminal amino
acids, while the N-terminus shows high homology with other herpes
viruses.37,38 We cannot exclude a C-terminal VCA-p18 antigen may
have resulted in higher specificities, however, a study by Fachiroh
et al examining IgA antibodies against the C-terminal VCA-p18 pep-
tide for NPC diagnosis showed lower sensitivity and specificity com-
pared to the newly described antibodies in this report.39 In contrast to
VCA-p18 and EBNA1 IgA antibodies, both IgA and IgG antibodies to
LF2 seem to be almost always present in EBER-ISH positive NPC
patients, and absent in control LSCCs and EBER-ISH-negative NPCs
(Figure 2). This clear distinction makes LF2 robust and potentially
attractive as a diagnostic and potentially also prospective biomarker.
Other than only differentiating EBV-positive from EBV-negative
NPCs, the low seroprevalence of LF2 IgG (3%) in control LSCCs
(Figure 2) indicates the high value of this marker for identifying indi-
viduals with EBV-positive NPCs, assuming healthy people have similar
EBV levels as individuals with LSCC. This could be especially impor-
tant for screening applications in endemic regions.
Little is known about the biological role of LF2 in NPC develop-
ment. The EBV protein interaction map shows that LF2 binds exclu-
sively to one other EBV protein, Rta (ie, BRLF1).40 Rta is one of two
transcriptional activators for controlling the switch from latent infec-
tion to the lytic replication cycle. LF2 overexpression has been shown
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to inhibit Rta by downregulating Rta activation of different early lytic
promoters, except its own; as a result, lytic activation is blocked.41
LF2 RNA was also found to be present in Burkitt lymphoma cell lines
during latency and in Burkitt lymphoma tumor biopsies.42
In our study, we applied HPV serology of high-risk HPV types
16, 18, 31, 33, 35, 45, 52 and 58 to all NPCs. It is the first time a sero-
logical definition is used to characterize HPV-positive NPCs. Valida-
tion with molecular tumor markers (p16, HPV DNA and RNA) showed
that the previously established HPV serology for OPC detection and
prediction17,20,21,43 can be applied equally for NPCs. Interestingly, all
18 HPV-driven NPCs are from white participants as observed previ-
ously in other studies12,14,44 compared to 21% of EBV-positive NPCs
being from people of color, half being from Asian countries. There
was no overlap (neither for molecular markers, nor for serology)
between EBV- and HPV-positive tumors, suggesting that there is no
interaction between the viruses in tumor development.
Unlike OPCs, which are mostly (≥90%) associated with HPV1645
and rarely with HPV16-related types such as HPV33, we identified
13 (72%) HPV16 positive, four (22%) HPV18 positive and one (6%)
HPV39 positive NPCs. This strengthens the hypothesis that HPV-
positive NPCs are not, or at least not always, an extension from an
oropharyngeal primary, as suggested by Singhi et al14 and instead can
represent a separate tumor entity. Multiple HPV types, also including
HPV16, HPV18, HPV39 and additionally HPV59, have been described
for HPV-positive NPCs before.46 However, the question whether
HPV truly causes NPC requires replication in bigger studies, and addi-
tional analyses to establish causality.
Survival analysis of HPV-positive vs EBV-positive and EBV/HPV-
negative NPCs did not reveal survival differences in our study. This
might be due to our small case groups. Dogan et al found that HPV-
positive NPCs have a similar overall survival to EBV-positive NPCs,
while EBV/HPV-negative NPCs have a worse overall survival.13
Another study by Stenmark et al however described a worse outcome
for HPV-positive and EBV/HPV-negative NPCs than for EBV-positive
NPCs.23 HPV-positive NPCs are only observed in low-incidence,
rather than endemic regions, which makes it difficult to obtain large
numbers of NPCs associated with HPV to evaluate different tumor
etiologies and patient prognosis with sufficient statistical power. In
contrast, it should be noted that the United Kingdom belongs to the
countries with relatively high HPV-prevalence in OPC.47
Comparing NPC cases positive for EBV or HPV and EBV/HPV-
negative NPCs, there is a significant difference between the histologi-
cal NPC subtypes. It is well established that nonkeratinizing NPCs
(WHO type II/III) are especially frequent in endemic regions, where
almost all tumors are EBV-positive, while EBV is absent in WHO type
I NPCs.48 In our study, 55 NPCs (92% of all 60 NPCs with histological
classification) are either WHO type II or III. Of those 55 NPCs, 45 are
positive for EBV (82%), only seven positive for HPV (13%) and three
negative for both EBV and HPV (5%). Of the four WHO type I NPCs,
none was positive for EBV. This strengthens the close association of
EBV-positive and WHO type II/III NPCs.
As suggested by Lo et al,49 we provide additional evidence that
HPV-positive NPCs are associated with keratinizing (WHO type I)
NPCs. Of four keratinizing NPCs, three were positive for HPV, and
the remaining one was negative for both EBV and HPV.
Keratinizing NPCs have also been associated with smoking and
alcohol use, a shared characteristic with other head and neck squa-
mous cell carcinomas.49 Of the four keratinizing NPCs we report,
two are former smokers and reported hazardous alcohol consump-
tion; one never smoked, but reported hazardous alcohol consump-
tion; and one was a former smoker, but nondrinker; in summary,
tobacco and alcohol exposure seems very high in this population.
Comparing the survival of the WHO type I, II and III cases, we did
not observe a difference in survival between these histological sub-
types (Figure S3). Larger studies are needed for a reliable compari-
son of survival data.
There is no statistical evidence for a difference in smoking
between EBV-positive, HPV-positive and EBV/HPV-negative NPCs.
However, it is noticeable that there is no current smoker in the
EBV/HPV-negative NPC group. Since EBV infection and smoking
have been described as independent risk factors,50 we expected more
current or former smokers in the group of EBV/HPV-negative NPCs.
Instead, we observed 55% of former smokers in this group (compared
to 50% for HPV-positive and 44% for EBV-positive NPC) and not a
single current smoker, while 23% of EBV-positive and 30% of HPV-
positive NPC cases were smoking at the time of diagnosis. In conse-
quence, NPCs which are neither associated with EBV, HPV and
smoking may be caused by other risk factors, which may include other
viral infections not considered in our study. The absence of any
smoker in the group of EBV/HPV-negative NPCs could also be based
on reporting bias. However, in our study, data on smoking is incom-
plete and our case groups are too small to draw final conclusions.
In summary, both EBV and HPV serology were included in our
analysis and validated with molecular tumor markers, and we have
shown that EBV and HPV serum antibodies correlate with the viral
status of NPC tumors. Individual serum antibodies or antibody pat-
terns represent an attractive, little invasive diagnostic marker that
does not require tumor tissue. The methods we presented here
should be applied in further case/control and prospective studies to
confirm results with larger case numbers (especially for HPV-
positive NPCs), healthy control groups, and prospectively collected
serum samples.
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